In Search of Wonderland: Heparin or Bivalirudin (pp. 155-158)
Authors: Rajeev Gupta, Neelesh Gupta, Jan Fedacko, Viola Mechirova, Daniel Pella, and RB Singh
Abstract: In patients with acute coronary syndrome (ACS) during and after percutaneous coronary intervention (PCI), antithrombotic therapy is essential to prevent adverse ischemic events, particularly stent thrombosis and reinfarction. However the benefits of antithrombotic therapy should be weighed against the risk of hemorrhagic complications, the occurrence of which has been strongly associated with subsequent mortality.